NCT00090545 2018-06-14A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent Prostate CancerNational Institutes of Health Clinical Center (CC)Phase 2 Completed46 enrolled 17 charts